Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody.
作者： Judith Pichler , Nima Memaran , Wolf Dietrich Huber , Christoph Aufricht , Bettina Bidmon‐Fliegenschnee
DOI: 10.1111/APA.15522
关键词:
摘要: AIM Anti-tumour necrosis factor (TNF)-α drugs are effective treatments for the management of moderate/severe Crohn's disease (CD), but treatment failure is common. In paediatric CD, there no data about use a third introduced subcutaneous TNF antibody golimumab. METHODS We evaluated efficacy golimumab adolescents with CD. Retrospective analyses were done in all 7 (5 girls) who received at median age 17 years 7.2 months. Paediatric activity index (PCDAI), full blood count, inflammatory markers, corticosteroids and adverse events recorded. RESULTS With golimumab, 5 children PCDAI responders 2 entered remission (PCDAI <10). Faecal calprotectin was significantly reduced after 4 weeks compared to baseline. Out five children, steroid withdrawal possible one reduction two cases. There serious side effects. CONCLUSION induced clinical response. Golimumab may be an rescue therapy refractory
sci-hub.st 参考文章(30)
Ofer Ben-Bassat, Anna Iacono, Sue P Irwin, Mark S Silverberg, Gordon R Greenberg, None, Tu1327a Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn's Disease: Open Label Experience Gastroenterology. ,vol. 142, ,(2012) , 10.1016/S0016-5085(12)63121-7
Gabor Hutas, Golimumab, a fully human monoclonal antibody against TNFalpha. Current Opinion in Molecular Therapeutics. ,vol. 10, pp. 393- 406 ,(2008)
Paul Emery, Roy M. Fleischmann, Larry W. Moreland, Elizabeth C. Hsia, Ingrid Strusberg, Patrick Durez, Peter Nash, Eric Jason B. Amante, Melvin Churchill, Won Park, Bernardo Antonio Pons-Estel, Mittie K. Doyle, Sudha Visvanathan, Weichun Xu, Mahboob U. Rahman, Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis & Rheumatism. ,vol. 60, pp. 2272- 2283 ,(2009) , 10.1002/ART.24638
William J Sandborn, Brian G Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss, Jewel Johanns, Omoniyi J Adedokun, Cynthia Guzzo, Jean-Frederic Colombel, Walter Reinisch, Peter R Gibson, Judith Collins, Gunnar Järnerot, Toshifumi Hibi, Paul Rutgeerts, PURSUIT-SC Study Group, Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. ,vol. 146, pp. 85- 95 ,(2014) , 10.1053/J.GASTRO.2013.05.048
F. Cornillie, D. Shealy, G. D'Haens, K. Geboes, G. Van Assche, J. Ceuppens, C. Wagner, T. Schaible, S. E. Plevy, S. R. Targan, P. Rutgeerts, Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics. ,vol. 15, pp. 463- 473 ,(2001) , 10.1046/J.1365-2036.2001.00956.X
David J. Shealy, Ann Cai, Kim Staquet, Audrey Baker, Eilyn R. Lacy, Laura Johns, Omid Vafa, George Gunn, Susan Tam, Sarah Sague, Dana Wang, Mike Brigham-Burke, Paul Dalmonte, Eva Emmell, Bill Pikounis, Peter J. Bugelski, Honghui Zhou, Bernard J. Scallon, Jill M. Giles-Komar, Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α mAbs. ,vol. 2, pp. 428- 439 ,(2010) , 10.4161/MABS.12304
William J Sandborn, Brian G Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss, Jewel Johanns, Omoniyi J Adedokun, Cynthia Guzzo, Jean–Frederic Colombel, Walter Reinisch, Peter R Gibson, Judith Collins, Gunnar Järnerot, Paul Rutgeerts, PURSUIT-Maintenance Study Group, Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. ,vol. 146, pp. 96- 109 ,(2014) , 10.1053/J.GASTRO.2013.06.010
Joel R. Rosh, Trudy Lerer, James Markowitz, Sri R. Goli, Petar Mamula, Joshua D. Noe, Marian D. Pfefferkorn, Kathleen T. Kelleher, Anne M. Griffiths, Subra Kugathasan, David Keljo, Maria Oliva-Hemker, Wallace Crandall, Ryan S. Carvalho, David R. Mack, Jeffrey S. Hyams, Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. The American Journal of Gastroenterology. ,vol. 104, pp. 3042- 3049 ,(2009) , 10.1038/AJG.2009.493
Nils Lonberg, Human antibodies from transgenic animals. Nature Biotechnology. ,vol. 23, pp. 1117- 1125 ,(2005) , 10.1038/NBT1135
James Markowitz, Kathy Grancher, Nina Kohn, Martin Lesser, Fredric Daum, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease Gastroenterology. ,vol. 119, pp. 895- 902 ,(2000) , 10.1053/GAST.2000.18144